Home MAPK S6 Kinase inhibitor - p38 MAPK inhibitor - ERK activator - JNK activator 3'-Hydroxypterostilbene

research use only

3'-Hydroxypterostilbene S6 Kinase inhibitor

Cat.No.S3940

3'-Hydroxypterostilbene (3'-HPT) is one of the active constituents of Sphaerophysa salsula and Pterocarpus marsupium which may be useful in treating different types of haematological malignancies. This compound, a natural pterostilbene analogue, effectively inhibits the growth of human colon cancer cells (IC50s of 9.0, 40.2, and 70.9 µM for COLO 205, HCT-116, and HT-29 cells, respectively) by inducing apoptosis and autophagy. It inhibits the PI3K/Akt/mTOR/p70S6K, and p38MAPK pathways and activates the ERK1/2, JNK1/2 MAPK pathways.
3'-Hydroxypterostilbene S6 Kinase inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 272.30

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S394001 DMSO]54 mg/mL]false]Ethanol]54 mg/mL]false]Water]Insoluble]false Purity: 99.55%
99.55

Chemical Information, Storage & Stability

Molecular Weight 272.30 Formula

C16H16O4

 Storage (From the date of receipt)
CAS No. 475231-21-1 Download SDF Storage of Stock Solutions

Synonyms 3'-HPT Smiles COC1=CC(=CC(=C1)C=CC2=CC(=C(C=C2)O)O)OC

Solubility

In vitro
Batch:

DMSO : 54 mg/mL ( (198.31 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 54 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
p70S6K [1]
p38MAPK [1]
In vitro
3'-Hydroxypterostilbene decreases cell growth in cultured human colon cancer cells (COLO 205, HCT-116, and HT-29) in a dose-dependent manner, with IC50 values of 9.0, 40.2, and 70.9 µM, respectively. This compound effectively inhibits the growth of human colon cancer cells by inducing apoptosis and autophagy. Treatment with this compound causes reduction of mitochondrial membrane potential and induction of caspase-3 and caspage-9, which is associated with the degradation of DFF-45 and PARP, precedes the onset of apoptosis. It significantly down-regulates phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinases (MAPKs) signalings including decreased the phosphorylation of mammalian target of rapamycin (mTOR)[1].
In vivo
3'-Hydroxypterostilbene by i.p. injection has anti-tumor efficacy gainst colon cancer through the inhibition of inflammation, metastasis, and angiogenesis as well as through the induction of apoptosis[1].
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01199250 Not yet recruiting
Lynch Syndrome|Recurrent Uterine Corpus Carcinoma|Stage I Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer
Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation
 January 2100 --
NCT05454306 Suspended
Clavicle Fracture
University of Minnesota
 January 9 2028 Not Applicable
NCT05118594 Not yet recruiting
Major Depressive Disorder|Dysthymic Disorder|Specific Phobia|Social Anxiety Disorder|Panic Disorder|Agoraphobia|Generalized Anxiety Disorder
National Council of Scientific and Technical Research Argentina
 February 2026 Not Applicable
NCT06077526 Not yet recruiting
Chronic Pain
Bridgewater College
 January 13 2026 Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map